Quinn Opportunity Partners LLC Purchases Shares of 16,500 Moderna, Inc. (NASDAQ:MRNA)

Quinn Opportunity Partners LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 16,500 shares of the company's stock, valued at approximately $686,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB increased its stake in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc bought a new position in Moderna in the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC boosted its holdings in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after buying an additional 664 shares during the last quarter. Crowley Wealth Management Inc. acquired a new stake in Moderna in the fourth quarter valued at $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its position in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after acquiring an additional 389 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Down 2.3 %

MRNA traded down $0.58 during mid-day trading on Thursday, reaching $24.61. 2,927,347 shares of the company traded hands, compared to its average volume of 11,396,458. The stock has a market capitalization of $9.52 billion, a P/E ratio of -2.65 and a beta of 2.23. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47. The company's fifty day moving average price is $31.10 and its 200-day moving average price is $40.37.

Analyst Ratings Changes

Several research firms have issued reports on MRNA. Royal Bank of Canada restated a "sector perform" rating and issued a $40.00 price objective on shares of Moderna in a research note on Tuesday, February 18th. Berenberg Bank lifted their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a report on Thursday, January 16th. Morgan Stanley lowered their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Bank of America reduced their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research report on Tuesday, February 11th. Finally, Citigroup assumed coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target on the stock. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Moderna has an average rating of "Hold" and a consensus price target of $58.70.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.